Response
We appreciate the comments of Dr Goldstein regarding the incidence of cancer seen with amlodipine in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT). 1 Because of the concern raised by Pahor et al, 2 we carefully reviewed each case of cancer with an independent group of oncologists. In view of the relatively small number of events, no firm conclusions could be reached regarding the risk of cancer associated with use of amlodipine. Additional cancer data, however, will be available in the next 2 to 3 years from several large-scale trials in which amlodipine is being compared with placebo or other antihypertensive strategies.
We believe that the reduction in the incidence of hospitalization for angina pectoris and the need for revascularization observed in PREVENT suggests a role for amlodipine in patients with coronary artery disease.
